Back to search

Article

CD38 as a Therapeutic Target

2006-11-01

Abstract excerpt

The CD38 molecule is well represented on cell surfaces in many cases of a variety of lymphoid tumors, notably multiple myeloma, AIDS-associated lymphomas, and post-transplant lymphoproliferations. As such, this molecule is a promising target for antibody therapy. After early disappointments, improved anti-CD38 antibodies of strong cytolytic potential have been described by 3 groups. First, a human IgG monoclonal a...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
4eeebd12-861b-5098-bf70-aae9d8e4c3be
DOI
10.2119/2006-00082.stevenson
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
CD38 as a Therapeutic TargetDOI 10.2119/2006-00082.stevenson
Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myelomaSemantic proximity
Role of CD38 Expression in Diagnosis and Pathogenesis of Chronic Lymphocytic Leukemia and Its Potential as Therapeutic TargetSemantic proximity
The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia–Microenvironment Interactions in Chronic Lymphocytic LeukemiaSemantic proximity
Targeting CD38 Across Autoimmune and Plasma Cell–Driven Immune-Mediated Diseases: Rationale, Clinical Evidence, and Emerging Therapeutic LandscapeSemantic proximity
Resistance Mechanisms towards CD38−Directed Antibody Therapy in Multiple MyelomaSemantic proximity
Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with DaratumumabSemantic proximity
Targeting CD38 with Daratumumab Monotherapy in Multiple MyelomaSemantic proximity
Targeting Attenuated Interferon-α to Myeloma Cells with a CD38 Antibody Induces Potent Tumor Regression with Reduced Off-Target Activity.Semantic proximity
Nanobodies effectively modulate the enzymatic activity of CD38 and allow specific imaging of CD38+ tumors in mouse models in vivoSemantic proximity
Long-term CD38 saturation by daratumumab interferes with diagnostic myeloma cell detectionSemantic proximity
The enzymatic activities of CD38 enhance CLL growth and trafficking: implications for therapeutic targeting.Semantic proximity
Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple MyelomaSemantic proximity
Select a neighboring publication to make it the new centre.